Publicaciones en las que colabora con MARÍA SAGRARIO GÓMEZ RUIZ (12)

2017

  1. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

    PLoS ONE, Vol. 12, Núm. 4

  2. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies

    Methods in Enzymology (Academic Press Inc.), pp. 175-198

2016

  1. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

    Neuroscience, Vol. 339, pp. 191-209

2007

  1. An overview on the biochemistry of the cannabinoid system

    Molecular Neurobiology, Vol. 36, Núm. 1, pp. 3-14

2005

  1. Effects on development

    Handbook of Experimental Pharmacology, Vol. 168, pp. 643-656

  2. Therapeutic potential of the endocannabinoid system in the brain

    Mini-Reviews in Medicinal Chemistry, Vol. 5, Núm. 7, pp. 609-617

  3. Tissue destruction in periodontitis: Bacteria or cytokines fault?

    Quintessence International, Vol. 36, Núm. 4, pp. 299-306

2004

  1. Cannabinoids and gene expression during brain development

    Neurotoxicity Research, Vol. 6, Núm. 5, pp. 389-401

  2. New knowledge of the pathogenesis of periodontal disease

    Quintessence International, Vol. 35, Núm. 9, pp. 706-716

2003

  1. Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain.

    Brain research. Developmental brain research, Vol. 147, Núm. 1-2, pp. 201-207

2002

  1. Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Δ9-tetrahydrocannabinol

    Neurotoxicity Research, Vol. 4, Núm. 3, pp. 211-218

  2. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease

    Neurotoxicity Research, Vol. 4, Núm. 7-8, pp. 601-608